Compounds > 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone
Page last updated: 2024-11-03

4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone and Pulmonary Eosinophilia

4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone has been researched along with Pulmonary Eosinophilia in 1 studies

4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases.

Pulmonary Eosinophilia: A condition characterized by infiltration of the lung with EOSINOPHILS due to inflammation or other disease processes. Major eosinophilic lung diseases are the eosinophilic pneumonias caused by infections, allergens, or toxic agents.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ikemura, T1
Schwarze, J1
Makela, M1
Kanehiro, A1
Joetham, A1
Ohmori, K1
Gelfand, EW1

Other Studies

1 other study available for 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone and Pulmonary Eosinophilia

ArticleYear
Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia.
    The Journal of pharmacology and experimental therapeutics, 2000, Volume: 294, Issue:2

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Animals; Bronch

2000